Phathom Pharmaceuticals Inc., a biopharmaceutical company focusing on gastrointestinal disease treatments, has announced the approval of new inducement awards for Jonathan Bentley, who has been appointed as Senior Vice President, Head of Sales. On May 1, 2025, the company's Board of Directors granted Bentley a non-qualified stock option to purchase 79,365 shares of common stock, with 25% vesting on May 1, 2026, and the rest vesting in 36 equal monthly installments. Additionally, Bentley received two restricted stock unit awards: 57,143 units vesting in three equal annual installments and 50,000 units vesting in two equal installments. These awards are part of the 2025 Employment Inducement Incentive Award Plan and are contingent on Bentley's continued service with the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。